Reaction

Mean Cell Haemoglobin Decreased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,813 reports · 69 co-occurring drugs

As of the last recalculation, Mean Cell Haemoglobin Decreased appears in 1,813 FAERS reports alongside 69 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 56.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Alemtuzumab	91	56.8	57.1
Clozapine	420	49.7	49.8
Dimenhydrinate	44	48.6	48.8
Diclofenac Potassium, Film Coated	28	38.8	38.9
Diclofenac Potassium Tablets	28	38.8	38.9
Diclofenac Potassium	28	30.2	30.3
Calcium Gluconate	31	30.0	30.1
Cortisone Acetate	28	26.4	26.5
Adalimumab-Fkjp	98	25.6	25.7
Adalimumab-Aaty	98	25.1	25.1
Adalimumab-Adaz	99	22.7	22.8
Ciclesonide	24	20.5	20.5
Sulfasalazine	130	20.5	20.5
Leflunomide	151	18.0	18.0
Hydroxychloroquine Sulfate	121	16.3	16.3
Tofacitinib Citrate	18	15.9	15.9
Desoximetasone	26	15.9	15.9
Tocilizumab	140	15.2	15.2
Cetirizine Hydrochloride Allergy	37	14.3	14.3
Cetirizine Hydrochloride Tablets	37	14.3	14.3
Aripiprazole Oral	47	13.4	13.4
Aripiprazole Orally Disintegrating	47	13.4	13.4
Cimetidine	11	13.2	13.2
Infliximab-Dyyb	29	11.6	11.6
Abatacept	127	11.2	11.3
Pseudoephedrine Hydrochloride	10	11.2	11.2
Fulvestrant	31	10.9	11.0
Diclofenac Sodium 1%	33	10.8	10.8
Diclofenac Sodium Topical	33	10.8	10.8
Diclofenac Sodium Topical Gel, 1%	33	10.8	10.8
Pseudoephedrine Hcl	10	10.5	10.5
Niraparib	20	10.4	10.5
Paliperidone	21	10.4	10.5
Everolimus	45	10.4	10.4
Nicotine Polacrilex Mini	13	10.0	10.0
Nicotine Polarilex	13	10.0	10.0
Naproxen	65	9.8	9.8
Rituximab	162	9.6	9.6
Cetirizine	55	8.4	8.4
Quetiapine Fumarate	21	8.3	8.3
Infliximab	143	8.1	8.1
Olanzapine	68	7.5	7.5
Tiotropium Bromide Inhalation Spray	7	7.2	7.2
Naproxen Sodium Tablet, Coated	7	6.0	6.0
Naproxen Sodium, Coated Tablets	7	6.0	6.0
Naproxen Sodium 220Mg	7	5.9	5.9
Aripiprazole	61	5.9	5.9
Lurasidone Hydrochloride	10	5.5	5.5
Ado-Trastuzumab Emtansine	4	5.5	5.5
Ranitidine	86	5.2	5.2
Tolvaptan	6	4.8	4.8
Golimumab	34	4.6	4.6
Asfotase Alfa	4	4.6	4.6
Somatropin	29	4.6	4.6
Fingolimod Hcl	34	4.6	4.6
Nicotine Polacrilex	15	4.5	4.5
Crizotinib	5	4.5	4.5
Eltrombopag Olamine	9	4.5	4.5
Tofacitinib	66	4.2	4.2
Dalfampridine	24	3.9	3.9
Polatuzumab Vedotin	3	3.5	3.5
Cannabidiol	7	3.4	3.4
Certolizumab Pegol	34	3.4	3.4
Methoxy Polyethylene Glycol-Epoetin Beta	3	3.1	3.1
Palbociclib	25	3.0	3.0
Lifitegrast	4	2.8	2.8
Isotretinoin	12	2.8	2.8
Emicizumab	3	2.8	2.8
Droxidopa	3	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.